Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Nereus Pharmaceuticals

Request full access

Discovery and development of therapeutics for the treatment of infectious diseases and inflammation

San Diego, United StatesFounded 1998Biotech & Life Sciences

About Nereus Pharmaceuticals

Nereus Pharmaceuticals, founded in 1998, was a biopharmaceutical firm headquartered in San Diego that specialized in deriving novel drug candidates from marine microbial sources. The company was established by a team that included William Fenical, Kobi M. Sethna, Michael A. Palladino, and Stan Fleming. Leveraging proprietary technology initially licensed from the University of California, San Diego, Nereus focused on cultivating and analyzing microorganisms from oceanic environments to identify bioactive compounds for therapeutic use.

The company's primary therapeutic area of focus was oncology. Its business model centered on the discovery, development, and eventual commercialization of these naturally sourced small molecule drugs. Nereus advanced two main candidates into clinical trials. The first, Plinabulin (NPI-2358), is a vascular disrupting agent derived from a marine fungus, designed to selectively cut off blood flow to solid tumors. The second, Marizomib (NPI-0052), is a proteasome inhibitor discovered from the marine bacterium *Salinispora tropica*, intended for treating various cancers including multiple myeloma, lymphomas, and leukemias. Throughout its operation, Nereus successfully raised significant capital, securing a total of $87.6 million over two funding rounds to advance its clinical programs.

A significant milestone in the company's history was the progress of its drug candidates through Phase I and II clinical trials, showing potential in treating conditions like non-small cell lung cancer. Ultimately, Nereus Pharmaceuticals was acquired by Triphase Research and Development in October 2012. Following the acquisition, the rights to Plinabulin were later acquired by BeyondSpring Pharmaceuticals, which continued its development.

Source: Dealroom company data

At a glance

Status
Operational
Founded
1998
Headquarters
San Diego, United States
Employees
8
Open positions
None listed
Dealroom signal
25.3/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotech & Life Sciences, Biotechnology, Healthcare Technologies, Biotech and Pharma, Hard Tech, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B

Funding history

5 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES EOther financing Jun 2010 $20M $80M Roche Venture Fund · Advent International · Alta Partners · Forward Ventures —
SERIES DOther financing Aug 2007 $45M $180M Astellas Venture —
Showing the latest 2 of 5 recorded eventsBook a demo for the full funding history →

Growth signals

Nereus Pharmaceuticals website traffic

Latest recorded traffic for Nereus Pharmaceuticals is 190 monthly website visits. Nereus Pharmaceuticals's team grew 0% over the past year.

Latest monthly visits190 1-year team growth0%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Nereus Pharmaceuticals in the San Diego ecosystem

Live from Dealroom

The Nereus Pharmaceuticals office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

14 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A5 investors entered at this stage

  • Gimv
  • JIF Capital
  • Alta Partners
  • Pacific Venture Group
  • Novartis Venture Fund

Series B and later9 investors entered at this stage

  • HBM Healthcare Investments
  • Advent International
  • InterWest Partners
  • HBM BioVentures
  • Red Abbey Venture Partners
  • Astellas Venture
  • Roche Venture Fund
  • Forward Ventures
  • Pacific Venture Capital
Team profiled 10 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
2 countries with
team presence
🇺🇸 United States75%
🇬🇷 Greece25%
2 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Nereus Pharmaceuticals on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Nereus Pharmaceuticals’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.